NurExone Biologic Inc. Enters Sublicense Agreement for U.S. Operations
On March 26, 2026, NurExone Biologic Inc., a biotechnology company developing exosome-based therapies, announced that its subsidiaries Exo-Top Inc. and NurExone Biologic Ltd. have entered into a sublicense agreement, granting Exo-Top certain rights under an existing license from June 23, 2020, with Technion Research and Development Foundation Ltd. and Ramot, according to GlobeNewswire PE. The agreement positions Exo-Top as a strategic U.S. subsidiary to support manufacturing, clinical advancement, and long-term value creation for naïve exosomes in the U.S.
Details of the Sublicense Agreement
Under the sublicense, NurExone Ltd. has granted Exo-Top rights from the original Tech License, which was amended after its initial date, to facilitate future manufacturing, development, and commercial activities in North America. No monetary consideration was paid by Exo-Top to NurExone Ltd. in connection with this sublicense, and the company does not expect any sublicense fees to be payable to TRDF as a result. Pursuant to the Tech License, NurExone is obligated to pay TRDF certain royalty fees upon reaching Phase II of clinical trials and additional royalties on commercialization, according to GlobeNewswire PE.
Role of Exo-Top in NurExone’s Strategy
Dr. Lior Shaltiel, Chief Executive Officer of NurExone, stated that the sublicense represents an important step in building Exo-Top as part of the company’s long-term U.S. strategy, aligning with plans for manufacturing, development, and commercialization in North America. Exo-Top, as NurExone’s wholly owned U.S. subsidiary, possesses a Master Cell Bank that ensures batch-to-batch consistency in exosome bioproduction, which is crucial for clinical translation and commercial readiness. This structure enhances strategic flexibility in a key market, as biotechnology firms often navigate regulatory environments across borders—a widely-known challenge in the sector.
About NurExone and Its Focus
NurExone Biologic Inc. is listed on the TSX Venture Exchange, OTCQB, and Frankfurt Stock Exchange, and it focuses on developing regenerative exosome-based therapies for central nervous system injuries. The company’s lead product, ExoPTEN, has demonstrated potential in this area, according to GlobeNewswire PE. As a broader context, exosome therapies represent an emerging field in biotechnology, where companies like NurExone aim to address unmet needs in regenerative medicine.
